Biotech Values

[ghmm]

CTMX:

That is something I wondered about when I was first looking at the company.
Yes competition is possible (inevitable) but I see them as having first mover advantage with significant partnerships already in place. Its really a relatively new development (I think the company has been in it for ~10 years). They do have patents (not a lot) 4 I believe and 100 or so pending (total worldwide). I also liked that they are continuing to move the technology (such as going outside of Oncology and advancing it for BiSpecifics).

I was not familiar with Igencia. A recent IPO (MRSN) is doing something similar (along the lines of delivering more drug to target).